A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Blood

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2003-03-0954PMID 14504104
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.

  2002cited by this paper
• T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.

  2002cited by this paper
• Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.

  2001cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl -positive leukemia in mice

  2001cited by this paper
• A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.

  2001cited by this paper
• HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.

  2001cited by this paper
• CML vaccines as a paradigm of the specific immunotherapy of cancer.

  2000cited by this paper
• Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.

  2000cited by this paper
• b3a2 BCR–ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia

  2000cited by this paper
• Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia

  2000cited by this paper
• A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct.

  1999cited by this paper
• Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients

  1999cited by this paper
• CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.

  1998cited by this paper
• Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.

  1998cited by this paper
• Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.

  1997cited by this paper
• Peptides derived from the whole sequence of BCR‐ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes

  1997cited by this paper
• HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.

  1997cited by this paper
• The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens.

  1997cited by this paper
• Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.

  1996cited by this paper
• Specific human cellular immunity to bcr-abl oncogene-derived peptides.

  1996cited by this paper
• BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.

  1996cited by this paper
• Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes

  1996cited by this paper
• Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes.

  1996cited by this paper
• Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.

  1995cited by this paper
• Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells.

  1995cited by this paper
• Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.

  1995cited by this paper
• Homozygous human TAP peptide transporter mutation in HLA class I deficiency.

  1994cited by this paper
• T cell immunity to the joining region of p210^ protein.

  1992cited by this paper
• T-cell immunity to the joining region of p210BCR-ABL protein.

  1992cited by this paper
• The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript

  1986cited by this paper
• Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene.

  1986cited by this paper
• The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.

  1986cited by this paper
• The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity.

  1985cited by this paper
• Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

  1985cited by this paper
• Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia

  1983cited by this paper
• A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

  1982cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper

• Immune Surveillance in Chronic Myeloid Leukemia: Tumor Antigen Expression and CD8+ T Cell Function in the Context of Treatment- Free Remission

  2025cites this paper
• Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

  2025cites this paper
• Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

  2025cites this paper
• Recent advances in therapeutic cancer vaccines

  2025cites this paper
• Harnessing phytochemicals: Innovative strategies to enhance cancer immunotherapy.

  2025cites this paper
• Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies

  2025cites this paper
• Identification of BRCA new prognostic targets and neoantigen candidates from fusion genes

  2024cites this paper
• Overview of saponin-producing species of Quillajaceae from a global perspective

  2024cites this paper
• DNA damage response and neoantigens: A favorable target for triple-negative breast cancer immunotherapy and vaccine development.

  2024cites this paper
• A bispecific nanosystem activates endogenous natural killer cells in the bone marrow for haematologic malignancies therapy

  2024cites this paper
• A Winning New Combination? Toward Clinical Application in Oncology

  2023cites this paper
• Neoantigens: promising targets for cancer therapy

  2023cites this paper
• Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to Onchocerca volvulus in Mice and Non-Human Primates

  2023cites this paper
• Sources of Cancer Neoantigens beyond Single-Nucleotide Variants

  2022cites this paper
• Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer.

  2022cites this paper
• Harnessing gene fusion-derived neoantigens for 'cold' breast and prostate tumor immunotherapy.

  2022cites this paper
• Therapeutic dendritic cell cancer vaccines in hematologic malignancies

  2021cites this paper
• Gene fusion neoantigens: Emerging targets for cancer immunotherapy.

  2021cites this paper
• T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy

  2021cites this paper
• Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving EPC2 and GULP1

  2021cites this paper
• Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects

  2021cites this paper
• A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.

  2021cites this paper
• Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire

  2020cites this paper
• Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

  2020cites this paper
• A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens

  2020cites this paper
• New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia

  2019cites this paper
• Can increased immunogenicity in chronic myeloid leukemia improve outcomes?

  2019cites this paper
• Alternative tumour-specific antigens

  2019cites this paper
• Anti-cancer vaccine therapy for hematologic malignancies: An evolving era.

  2018cites this paper
• Vaccine therapy in hematologic malignancies.

  2018cites this paper
• Myeloid Leukemia Vaccines

  2018cites this paper
• The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.

  2018cites this paper
• Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.

  2017cites this paper
• Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?

  2017influential citation
• Current Management Approaches of Chronic Myeloid Leukemia

  2017influential citation
• Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches

  2017cites this paper
• Hematologic neoplasms: Dendritic cells vaccines in motion.

  2017cites this paper
• Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer

  2017cites this paper
• Immunological off-target effects of imatinib

  2016cites this paper
• Cancer Immune Therapy in Clinic: 2016

  2016cites this paper
• participant in human DLBCLs with REL gene amplifications.

  2016cites this paper
• PR1 Peptide Vaccine Induces Specific Immunity With Clinical Responses In Myeloid Malignancies

  2016cites this paper
• Beyond tyrosine kinase inhibitors: Combinations and other agents.

  2016cites this paper
• Peptide Vaccination Strategies Targeting Commonly Shared Cancer Antigens

  2016cites this paper
• Biology of the Human Graft‐versus‐Tumor Response and How to Exploit It

  2016cites this paper
• DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties

  2016cites this paper
• Cancer Neoantigens and Applications for Immunotherapy

  2015cites this paper
• T cell exhaustion and Interleukin 2 downregulation.

  2015cites this paper
• Haematological malignancies: at the forefront of immunotherapeutic innovation

  2015cites this paper
• Is there a need to identify novel tumour antigens as targets for immunotherapy clinical trials for the removal of minimal residual disease in haematological malignancies

  2015cites this paper
• Immunological Control of Chronic Myeloid Leukemia Leading to Treatment-Free

  2014cites this paper
• Peptide vaccines for hematological malignancies: a missed promise?

  2014cites this paper
• Towards More Specificity and Effectivity in the Antileukemia Immune Response

  2014cites this paper
• Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies

  2014cites this paper
• Can we cure CML without transplantation

  2014cites this paper
• Immunology and Immunotherapy of Chronic Myeloid Leukemia

  2014cites this paper
• Developing strategies in the immunotherapy of leukemias.

  2013cites this paper
• Rekombinantní vakcíny proti solidním a hematologickým nádorům: vývoj a stanovení jejich účinnosti

  2013cites this paper
• Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

  2013cites this paper
• Tumor-Associated Antigens

  2013cites this paper
• Immunotherapy in pediatric hemato-oncology

  2013cites this paper
• Peptide Vaccines for Myeloid Leukemias

  2013cites this paper
• The role of peptide and DNA vaccines in myeloid leukemia immunotherapy

  2013cites this paper
• through off-target inhibition of kinases important for cell signaling Tyrosine kinase inhibitors impair B-cell immune responses in CML

  2013cites this paper
• Pushing the limits of targeted therapy in chronic myeloid leukaemia

  2012cites this paper
• Detecting T-cell reactivity to whole cell vaccines

  2012cites this paper
• New insights into antigen specific immunotherapy for chronic myeloid leukemia

  2012cites this paper
• SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group

  2012cites this paper
• Biological therapy and the immune system in patients with chronic myeloid leukemia

  2012cites this paper
• Treatment of Chronic Myeloid Leukaemia: Current Practice and Future Prospects

  2012cites this paper
• 1 Treatment of Chronic Myeloid Leukaemia : Current Practice and Future Prospects

  2012cites this paper
• Development of an Effective Therapy for CML

  2012cites this paper
• The bone marrow stroma in hematological neoplasms—a guilty bystander

  2011cites this paper
• Peptide vaccine therapy for leukemia

  2011cites this paper
• Clinical peptide vaccination trials for leukemia patients

  2011cites this paper
• Development of an Effective Therapy for Chronic Myelogenous Leukemia

  2011cites this paper
• Saponin QS-21 adjuvants in cancer vaccines

  2011cites this paper
• Evaluation of current cancer immunotherapy: hemato-oncology.

  2011cites this paper
• Vaccines as consolidation therapy for myeloid leukemia

  2011cites this paper
• BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients.

  2011cites this paper
• Characterization of a Monoclonal Antibody Specific for Novel Bcr/Abl Out-of-Frame Fusion Proteins

  2011cites this paper
• Tumor-Specific Mutations as Targets for Cancer Immunotherapy

  2011cites this paper
• Studies on the immunogenicity of tumour associated antigens in leukaemia

  2011cites this paper
• Novel Immunologic Adjuvants

  2011cites this paper
• Immunotherapy for myeloproliferative neoplasms (MPN).

  2011cites this paper
• Vaccination Strategies in Lymphomas and Leukaemias

  2011cites this paper
• Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia

  2011cites this paper
• K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

  2010cites this paper
• Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

  2010cites this paper
• Myeloproliferative neoplasms: new translational therapies.

  2010cites this paper
• WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE

  2010influential citation
• Chemotherapy and radiotherapy: cryptic anticancer vaccines.

  2010cites this paper
• Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

  2010cites this paper
• Immunotherapy of chronic myeloid leukemia: present state and future prospects.

  2010cites this paper
• eview hemotherapy and radiotherapy : Cryptic anticancer vaccines

  2010cites this paper
• Human leukocyte antigen class I alleles and the risk of chronic myelogenous leukemia: a meta-analysis

  2010cites this paper
• Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand1

  2009cites this paper
• Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.

  2009cites this paper
• The biological basis for immunotherapy in patients with chronic myelogenous leukemia.

  2009cites this paper
• Charakterisierung einer hABL-spezifischen CD4+-T-Zellantwort und die Anwendung des AdEtOH als Katalysator der Peptidbeladung

  2009cites this paper